Show simple item record

AuthorEl Dakkak, Bisan
AuthorTaneera, Jalal
AuthorEl-Huneidi, Waseem
AuthorAbu-Gharbieh, Eman
AuthorHamoudi, Rifat
AuthorSemreen, Mohammad H.
AuthorSoares, Nelson C.
AuthorAbu-Rish, Eman Y.
AuthorAlkawareek, Mahmoud Y.
AuthorAlkilany, Alaaldin M.
AuthorBustanji, Yasser
Available date2024-08-28T04:23:43Z
Publication Date2024
Publication NameBiomolecules and Therapeutics
ResourceScopus
ISSN19769148
URIhttp://dx.doi.org/10.4062/biomolther.2023.149
URIhttp://hdl.handle.net/10576/58236
AbstractApoptosis, programmed cell death pathway, is a vital physiological mechanism that ensures cellular homeostasis and overall cellular well-being. In the context of cancer, where evasion of apoptosis is a hallmark, the overexpression of anti-apoptotic proteins like Bcl2, Bcl-xL and Mcl-1 has been documented. Consequently, these proteins have emerged as promising targets for therapeutic interventions. The BCL-2 protein family is central to apoptosis and plays a significant importance in determining cellular fate serving as a critical determinant in this biological process. This review offers a comprehensive exploration of the BCL-2 protein family, emphasizing its dual nature. Specifically, certain members of this family promote cell survival (known as anti-apoptotic proteins), while others are involved in facilitating cell death (referred to as pro-apoptotic and BH3-only proteins). The potential of directly targeting these proteins is examined, particularly due to their involvement in conferring resistance to traditional cancer therapies. The effectiveness of such targeting strategies is also discussed, considering the tumor's propensity for anti-apoptotic pathways. Furthermore, the review highlights emerging research on combination therapies, where BCL-2 inhibitors are used synergistically with other treatments to enhance therapeutic outcomes. By understanding and manipulating the BCL-2 family and its associated pathways, we open doors to innovative and more effective cancer treatments, offering hope for resistant and aggressive cases.
Languageen
PublisherKorean Society of Applied Pharmacology
SubjectApoptosis
BCL-2 protein
BH3-mimetic drugs
Nanotechnology
Natural compounds
Venetoclax
TitleUnlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy
TypeArticle Review
Pagination267-280
Issue Number3
Volume Number32
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record